Search

Your search keyword '"Fiedler, Walter"' showing total 1,262 results

Search Constraints

Start Over You searched for: Author "Fiedler, Walter" Remove constraint Author: "Fiedler, Walter"
1,262 results on '"Fiedler, Walter"'

Search Results

1. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols

2. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia

4. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

5. Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

6. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

7. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

9. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

12. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL

13. Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy

14. Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19

15. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

16. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

17. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

22. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

24. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group

25. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

26. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

27. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

28. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

29. Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia.

30. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro

32. S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

33. S114: OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS

34. P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13

35. P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY

37. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

40. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

43. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

45. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

46. An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

47. Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia.

48. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option

49. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

50. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia

Catalog

Books, media, physical & digital resources